TY - JOUR
T1 - Systemic Immune-Inflammation Index and Mortality in Testicular Cancer
T2 - A Systematic Review and Meta-Analysis
AU - Salazar-Valdivia, Farley E.
AU - Valdez-Cornejo, Valeria A.
AU - Ulloque-Badaracco, Juan R.
AU - Hernandez-Bustamante, Enrique A.
AU - Alarcón-Braga, Esteban A.
AU - Mosquera-Rojas, Melany D.
AU - Garrido-Matta, Diana P.
AU - Herrera-Añazco, Percy
AU - Benites-Zapata, Vicente A.
AU - Hernandez, Adrian V.
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/3
Y1 - 2023/3
N2 - The systemic immune-inflammation index (SIII) is a marker studied in multiple types of urologic cancer. This systematic review evaluates the association between SIII values with overall survival (OS) and progression-free survival (PFS) in testicular cancer. We searched observational studies in five databases. The quantitative synthesis was performed using a random-effects model. The risk of bias was assessed using the Newcastle–Ottawa Scale (NOS). The only measure of the effect was the hazard ratio (HR). A sensitivity analysis was performed according to the risk of bias in the studies. There were 833 participants in a total of 6 cohorts. We found that high SIII values were associated with worse OS (HR = 3.28; 95% CI 1.3–8.9; p < 0.001; I2 = 78) and PFS (HR = 3.9; 95% CI 2.53–6.02; p < 0.001; I2 = 0). No indication of small study effects was found in the association between SIII values and OS (p = 0.5301). High SIII values were associated with worse OS and PFS. However, further primary studies are suggested to enhance the effect of this marker in different outcomes of testicular cancer patients.
AB - The systemic immune-inflammation index (SIII) is a marker studied in multiple types of urologic cancer. This systematic review evaluates the association between SIII values with overall survival (OS) and progression-free survival (PFS) in testicular cancer. We searched observational studies in five databases. The quantitative synthesis was performed using a random-effects model. The risk of bias was assessed using the Newcastle–Ottawa Scale (NOS). The only measure of the effect was the hazard ratio (HR). A sensitivity analysis was performed according to the risk of bias in the studies. There were 833 participants in a total of 6 cohorts. We found that high SIII values were associated with worse OS (HR = 3.28; 95% CI 1.3–8.9; p < 0.001; I2 = 78) and PFS (HR = 3.9; 95% CI 2.53–6.02; p < 0.001; I2 = 0). No indication of small study effects was found in the association between SIII values and OS (p = 0.5301). High SIII values were associated with worse OS and PFS. However, further primary studies are suggested to enhance the effect of this marker in different outcomes of testicular cancer patients.
KW - meta-analysis
KW - overall survival
KW - progression free survival
KW - systemic immune-inflammation index
KW - testicular cancer
UR - http://www.scopus.com/inward/record.url?scp=85149755948&partnerID=8YFLogxK
U2 - 10.3390/diagnostics13050843
DO - 10.3390/diagnostics13050843
M3 - Artículo de revisión
AN - SCOPUS:85149755948
SN - 2075-4418
VL - 13
JO - Diagnostics
JF - Diagnostics
IS - 5
M1 - 843
ER -
